Analyst Rami Katkhuda of LifeSci Capital maintained a Buy rating on Eledon Pharmaceuticals (ELDN – Research Report), retaining the price ...

Leerink Partners analyst Thomas Smith has reiterated their bullish stance on ELDN stock, giving a Buy rating yesterday. Thomas Smith’s ...

Eledon's lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The ...

Eledon’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The ...

One such molecule is the CD40L, which engages CD40 on dendritic and B cells of the immune system, enabling T cells to become activated as a result. Rodent studies using coreceptor blockade with ...

In fact, Wilkinson hopes an agreement between the Pathways Alliance consortium, Ottawa and Alberta can soon be reached to get one of the world’s largest carbon capture networks moving ...

“Therefore, I think it is important for us to then think … how do we create a lot more choices, a lot more flexible pathways to cater to the needs of the different students and also to meet ...

The proposed pathway would cross through the VIA Rail station property. However, staff say it's pausing the EA study because VIA Rail's future redevelopment plans for the site are unknown.

Conversely, the non-canonical pathway is specifically activated by a selective group of TNF-family cytokines, including lymphotoxin (LT), receptor activator of NF-κB ligand (RANKL), CD40 ligand (CD40L ...